Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 9/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31279507 | 1.00 | KHK (0.58) | KHKADRB1MAP4K1PIM1PIM3 | |
| SCHEMBL23711751 | 0.91 | ADRB1 (0.63) | KHKADRB1MAP4K1PIM1PIM3 | |
| SCHEMBL31278709 | 0.91 | ADRB1 (0.63) | KHKADRB1MAP4K1PIM1PIM3 | |
| SCHEMBL31279811 | 0.87 | ADRB1 (0.58) | KHKADRB1PIM1PIM3PIM2 | |
| SCHEMBL23711728 | 0.87 | ADRB1 (0.58) | KHKADRB1PIM1PIM3PIM2 | |
| SCHEMBL23711767 | 0.83 | KHK (0.51) | KHKADRB1MAP4K1PIM1PIM3 | |
| SCHEMBL31279859 | 0.83 | KHK (0.51) | KHKADRB1MAP4K1PIM1PIM3 | |
| SCHEMBL23711741 | 0.81 | KHK (0.56) | KHKPIM1PIM3PIM2IRAK4 | |
| SCHEMBL31278861 | 0.81 | KHK (0.56) | KHKPIM1PIM3PIM2IRAK4 | |
| SCHEMBL23711742 | 0.80 | KHK (0.74) | KHKIRAK4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | KHK, GCK, FN3K | KHK 1/4885ADRB1 1194/4885MAP4K1 74/4885 |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | KHK, GCK, HK1 | KHK 1/4885ADRB1 487/4885MAP4K1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.